GlassScriptPhysician profile
Brian L Revis
NPI 1023219052
$4,454.97
in general payments reported to CMS, 2019-2025
32 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $176 · 2021: $407 · 2022: $450 · 2023: $753 · 2024: $1,148 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,804 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,803.79 |
| Education | $106.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $717.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $657.55 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.47 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $314.33 | 2023-2025 | Thiola |
| Vifor Pharma, INC. | $275.21 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $270.37 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $230.29 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $209.48 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $141.33 | 2020-2023 | Injectafer |
| Mallinckrodt Enterprises LLC | $112.76 | 2019 | |
| Mallinckrodt Hospital Products INC. | $107.74 | 2020-2025 | Terlivaz, Acthar |
| Horizon Therapeutics Plc | $106.91 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $99.58 | 2019-2023 | Rayaldee |
| Nxstage Medical, INC. | $71.92 | 2019 | |
| Csl Behring | $66.89 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $63.38 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $59.10 | 2022-2023 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $51.46 | 2025 | |
| Bard Peripheral Vascular, INC. | $50.67 | 2023-2025 | Covera |
| Fresenius USA Marketing, INC. | $48.13 | 2023-2024 | Velphoro |
| Alexion Pharmaceuticals, INC. | $45.81 | 2024 | Ultomiris |
| Novo Nordisk INC | $44.44 | 2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $40.91 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $37.83 | 2021-2022 | |
| Radius Health, INC. | $37.03 | 2025 | Tymlos |
| Apellis Pharmaceuticals, INC. | $35.23 | 2025 | Empaveli |
| Lilly USA, LLC | $33.73 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $24.74 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.27 | 2024 | Crysvita |
| Akebia Therapeutics INC | $20.16 | 2025 | Vafseo |
| Alnylam Pharmaceuticals INC. | $13.44 | 2021 | |
| Renalytix Ai, INC. | $13.21 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Revis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.